Abstract
Natural killer (NK) cell therapy began decades ago with administration of small doses of minimally-characterized cells known as cytokine-induced or lymphokine-activated killer cells (CIK or LAK, respectively). Methods and conditions that enabled the broad adoption of T cell therapies have often been less effective for NK cells, but in the last 15 years, new NK-specific advances in selection, differentiation, and ex vivo expansion hav e made possible the infusion of large doses of pure and potent NK cell products. Also, NK cells have been more resistant to the genetic modification approaches utilized for engineering T cells, but in the last 5 years several robust approaches for NK cell modification have advanced to the clinic. Thus, a tremendous surge in NK cell clinical trials has been seen recently. Here, we present a focused perspective on the key developments in NK cell therapy that differentiate it from T cell therapies and discuss areas that are key to their clinical and commercial success- both current advancements and hurdles that remain to be addressed.
| Original language | English |
|---|---|
| Pages (from-to) | 812-825 |
| Number of pages | 14 |
| Journal | Cytotherapy |
| Volume | 27 |
| Issue number | 7 |
| DOIs | |
| State | Published - Jul 2025 |
Keywords
- cellular therapy
- chimeric antigen receptor
- clinical trials
- gene editing
Fingerprint
Dive into the research topics of 'Dark NKnight rising: a current perspective on NK cell and CAR-NK cell therapy'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver